Welcome to our dedicated page for Theratechnologies SEC filings (Ticker: THTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Theratechnologies Inc. (THTX) SEC filings page provides access to the company’s historical U.S. regulatory disclosures as a former Nasdaq-listed issuer. As a foreign private issuer, Theratechnologies filed reports such as Form 6-K to furnish press releases, material change reports, proxy materials, and other information to U.S. investors, and later a Form 25 in connection with the removal of its common shares from listing and registration on the Nasdaq Capital Market.
Recent filings include multiple Form 6-K submissions dated in 2025, which attach documents such as press releases announcing the availability of EGRIFTA WR (tesamorelin) for injection in the United States, notices and circulars for a special meeting of shareholders to consider an arrangement with CB Biotechnology (an affiliate of Future Pak), and materials relating to the company’s second quarter 2025 financial results. Additional Form 6-K filings provide the arrangement agreement itself, support and voting agreements with directors and senior officers, and a material change report describing the acquisition transaction.
A key document for understanding the trading status of THTX is the Form 25 filed on September 25, 2025 by Nasdaq Stock Market LLC. This notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 identifies Theratechnologies Inc. as the issuer and its common shares as the affected class of securities. It confirms Nasdaq’s action to strike the company’s common shares from listing and withdraw their registration on the exchange, following completion of the plan of arrangement under which an affiliate of Future Pak acquired all issued and outstanding shares.
Through this filings page, users can review how Theratechnologies communicated major events—such as its acquisition, special meeting process, and product-related announcements—to U.S. regulators and investors. Stock Titan’s tools can surface the most relevant Form 6-K submissions, highlight the content of attached press releases and circulars, and draw attention to structural filings like Form 25 that mark the end of THTX as a listed security. This historical record helps investors and researchers trace the company’s regulatory history leading up to its transition from a public issuer to a privately held affiliate of Future Pak.
Summer Road LLC filed a Schedule 13G reporting beneficial ownership of 2,683,591 Common Shares of Theratechnologies Inc. (CUSIP 88338H704), representing 5.84% of the 45,980,019 shares outstanding cited from the issuer's Form 20-F. The Reporting Person is a Delaware family office that holds these shares through investment management agreements with two Family Clients, identified as Cap 1 LLC and East River Partners Ltd. The filing states the shares are held passively and were not acquired to influence control of the issuer.
Theratechnologies Inc. submitted a Form 25 notice (Commission File No. 001-35203) indicating removal of its class of securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing states the Exchange has complied with the rules for striking the securities and that the issuer has complied with voluntary withdrawal requirements. Contact and address details for the issuer are provided.
Schedule 13G/A (Amendment 3) filed by Morgan Stanley discloses that its ownership in Theratechnologies Inc. (THTX) has fallen below the 5 % reporting threshold. As of 30 Jun 2025, the bank beneficially owns 858,614 common shares (CUSIP 88338H704), equal to 1.9 % of the outstanding class.
- Sole voting power: 0 shares
- Shared voting power: 852,939 shares
- Sole dispositive power: 0 shares
- Shared dispositive power: 858,614 shares
The filer is classified as a parent holding company/control person (HC, CO). Morgan Stanley certifies the shares are held in the ordinary course of business and not with intent to influence control. The amendment serves to notify investors that Morgan Stanley is no longer a 5 %+ beneficial owner of THTX.
FAQ
What is the current stock price of Theratechnologies (THTX)?
What is the market cap of Theratechnologies (THTX)?
